Genetic polymorphisms in interleukin-1β (rs1143634) and interleukin-8 (rs4073) are associated with survival after resection of intrahepatic cholangiocarcinoma.
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
28 07 2023
28 07 2023
Historique:
received:
02
02
2023
accepted:
26
07
2023
medline:
31
7
2023
pubmed:
29
7
2023
entrez:
28
7
2023
Statut:
epublish
Résumé
Intrahepatic cholangiocarcinoma (iCCA) is a rare, understudied primary hepatic malignancy with dismal outcomes. Aiming to identify prognostically relevant single-nucleotide polymorphisms, we analyzed 11 genetic variants with a role in tumor-promoting inflammation (VEGF, EGF, EGFR, IL-1B, IL-6, CXCL8 (IL-8), IL-10, CXCR1, HIF1A and PTGS2 (COX-2) genes) and their association with disease-free (DFS) and overall survival (OS) in patients undergoing curative-intent surgery for iCCA. Genomic DNA was isolated from 112 patients (64 female, 48 male) with iCCA. Germline polymorphisms were analyzed with polymerase chain reaction-restriction fragment length polymorphism protocols. The IL-1B +3954 C/C (73/112, hazard ratio (HR) = 1.735, p = 0.012) and the IL-8 -251 T/A or A/A (53/112 and 16/112, HR = 2.001 and 1.1777, p = 0.026) genotypes were associated with shorter OS in univariable and multivariable analysis. The IL-1B +3954 polymorphism was also associated with shorter DFS (HR = 1.983, p = 0.012), but this effect was not sustained in the multivariable model. A genetic risk model of 0, 1 and 2 unfavorable alleles was established and confirmed in multivariable analysis. This study supports the prognostic role of the IL-1B C+3954T and the IL-8 T-251A variant as outcome markers in iCCA patients, identifying patient subgroups at higher risk for dismal clinical outcomes.
Identifiants
pubmed: 37507547
doi: 10.1038/s41598-023-39487-7
pii: 10.1038/s41598-023-39487-7
pmc: PMC10382511
doi:
Substances chimiques
Interleukin-1beta
0
Interleukin-8
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
12283Informations de copyright
© 2023. The Author(s).
Références
Cancer Immunol Res. 2021 Mar;9(3):309-323
pubmed: 33361087
J Mol Evol. 2005 Nov;61(5):691-6
pubmed: 16205979
Clin Cancer Res. 2016 Aug 1;22(15):3924-36
pubmed: 26957562
Gut. 2022 Aug;71(8):1669-1683
pubmed: 35580963
Nat Rev Gastroenterol Hepatol. 2020 Sep;17(9):557-588
pubmed: 32606456
J Hepatol. 2020 Nov;73(5):1118-1130
pubmed: 32505533
Cancers (Basel). 2021 Jul 21;13(15):
pubmed: 34359564
J Immunol. 1994 Dec 15;153(12):5682-8
pubmed: 7527448
Cancer Cell. 2021 Jun 14;39(6):866-882.e11
pubmed: 33930309
J Hepatol. 2020 Jan;72(1):95-103
pubmed: 31536748
Ann Oncol. 2008 Oct;19(10):1734-41
pubmed: 18550579
J Clin Gastroenterol. 2009 Mar;43(3):233-9
pubmed: 18542040
Mol Cancer Res. 2017 Jan;15(1):3-14
pubmed: 27678171
Int J Mol Sci. 2018 Jul 24;19(8):
pubmed: 30042333
Clin Cancer Res. 2008 Dec 1;14(23):7884-95
pubmed: 19047118
Eur J Surg Oncol. 2019 Aug;45(8):1468-1478
pubmed: 31053477
Liver Cancer. 2022 Jan 25;11(2):162-173
pubmed: 35634429
Immunol Rev. 2018 Jan;281(1):197-232
pubmed: 29248002
J Periodontal Res. 2021 Jun;56(3):501-511
pubmed: 33638191
Nat Med. 2005 Sep;11(9):925-7
pubmed: 16145572
Pharmacogenet Genomics. 2009 Feb;19(2):95-102
pubmed: 18987561
Immunity. 2019 Apr 16;50(4):778-795
pubmed: 30995499
Lancet Oncol. 2019 May;20(5):663-673
pubmed: 30922733
Cancer Immunol Res. 2020 May;8(5):660-671
pubmed: 32161110
Int J Mol Sci. 2020 Oct 06;21(19):
pubmed: 33036244
Liver Int. 2019 May;39 Suppl 1:19-31
pubmed: 30851228
JAMA Surg. 2014 Jun;149(6):565-74
pubmed: 24718873
HPB (Oxford). 2020 Mar;22(3):437-444
pubmed: 31383591
Eur J Clin Invest. 1992 Jun;22(6):396-402
pubmed: 1353022
Cell. 2006 Jan 13;124(1):175-89
pubmed: 16413490
Proc Natl Acad Sci U S A. 2019 Jan 22;116(4):1361-1369
pubmed: 30545915
Epidemiol Infect. 2010 Apr;138(4):512-8
pubmed: 19719901
Hepatology. 2020 Sep;72(3):965-981
pubmed: 31875970
Drug Metab Lett. 2007 Jan;1(1):23-30
pubmed: 19356014
BMC Cancer. 2016 May 20;16:322
pubmed: 27206490
Nat Med. 2005 Sep;11(9):992-7
pubmed: 16127434
Ann Oncol. 2010 Jan;21(1):78-86
pubmed: 19622587
Langenbecks Arch Surg. 2019 Nov;404(7):885-894
pubmed: 31734715
Oncoimmunology. 2018 Aug 1;7(9):e1474319
pubmed: 30228942